EMA accepts Intas Pharma’s MAA for DMB-3115
herapeutic equivalence and safety confirmed between DMB-3115 and Stelara in global phase III
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Intas Pharma
The animal-human health connect
Pharma industry stakeholders shed light on several aspects and factors associated with the ‘one health’ concept and the veterinary…
Intas and Axantia sign licence and supply agreement for Ranibizumab biosimilar in Middle East
Under the terms of this agreement, Axantia will register, hold the marketing authorisation and commercialise Ranibizumab in…
Intas enters into agreement with Meiji and Dong-A ST to commercialise DMB-3115
Under the terms of the agreement, Intas has been granted exclusive licence rights to commercialise DMB-3115 worldwide, excluding…
Intas gets DCGI nod for clinical trials of hyperimmune globulin for COVID-19 treatment
It can be an important therapeutic option that can potentially help combat the disease until a vaccine is available, states the…
Naari completes acquisition of ANDAs from Intas Pharmaceuticals
The portfolio acquired comprises eight US FDA approved ANDAs and two products pending approval Naari Pharma has entered…